ArticleScientific reports2025
Risk of incident gout in rheumatoid arthritis from a nationwide cohort study in South Korea.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) coexisting with gout is considered rare, with only few case studies reporting this coexistence. This study aimed to evaluate the association between RA and subsequent gout risk in South Korea, considering the serostatus (seropositive RA [SPRA], seronegative RA [SNRA]) and type of biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). This nationwide, population-based cohort study analyzed 34,356 patients newly diagnosed with RA between 2010 and 2017 and 103,068 matched non-RA participants (1:3 ratio based on age and sex). The incident gout was defined according to the claims database diagnostic code for gout. RA patients had a 2.7-fold higher risk of developing gout than non-RA participants (95% confidence interval [CI]: 2.63-2.80). Patients with SPRA and SNRA had a higher risk of gout than non-RA participants, with an adjusted hazard ratio (aHR) of 2.79 and 2.56, respectively. The risk of gout was slightly higher in SPRA than in SNRA (aHR 1.07). RA patients using b/tsDMARDs had lower risk of gout (aHR, 1.93) than those not using these medications (aHR, 2.78). Contrary to common perceptions, both SPRA and SNRA were associated with a higher risk of gout, with slightly higher risk in SPRA than in SNRA. Using b/tsDMARDs may reduce the risk of gout in patients with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.